BioStock: Respiratorius’ CEO looks forward to a new eventful year

2020 was certainly a special year for drug developer Respiratorius that during the year initiated an exit process with its main candidate VAL001. At the same time, more resources are being devoted to the company’s bronchial relaxation drug RESP9000, which is currently in preclinical stage. BioStock has contacted the company’s CEO Johan Drott to get his view on 2020 and the coming year.

Read the full article at biostock.se:

https://www.biostock.se/en/respiratorius-ceo-looks-forward-to-a-new-eventful-year/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se